Conditions: Cerebral Infarction
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 90
Healthy volunteers: no

Brief summary:
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction. The study will assess incidence and tolerability of bleeding, major adverse cardiac events, all adverse events, and effect on expression of markers of inflammation.

Detailed description:

Arms:
arm 1: Vorapaxar oral tablets; once daily for 60 days + Aspirin. arm 2: Vorapaxar oral tablets; once daily for 60 days + Aspirin. arm 3: Placebo oral tablets; once daily for 60 days + Aspirin

Interventions: intervention 1: Vorapaxar 2.5 mg intervention 2: Vorapaxar 1 mg intervention 3: Placebo intervention 4: Aspirin 75-150 mg
Intervention descriptions: intervention 1: Oral tablets; once daily for 60 days. intervention 2: Oral tablets; once daily for 60 days intervention 3: oral tablets; once daily for 60 days intervention 4: oral tablets; once daily for 60 days

Protocol document: